Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A long term, prospective, multicentre, non interventional study assessing safety and efficacy of ocrelizumab treatment in Germany

Next Previous
Trial Profile

A long term, prospective, multicentre, non interventional study assessing safety and efficacy of ocrelizumab treatment in Germany

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CONFIDENCE

Most Recent Events

  • 13 Oct 2023 Results (n=500; data cut-off: 14 Oct 2022) of effectiveness analysis analyzed in patients with primary progressive MS (PPMS) in subgroups divided by EDSS score (0-5.5 vs. >5.5-6.5) at baseline treated with OCR for up to two years presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 13 Oct 2023 Results (n=2743) assessing the safety per treatment year (year1-4) of OCR in patients with relapsing multiple sclerosis and primary progressive multiple sclerosis, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
  • 28 Jun 2022 Interim results (n=2496) reporting preliminary real-world adherence and persistence data of patients with relapsing MS and primary progressive MS presented at the 8th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top